dexrazoxane
Trade name: zinecard
Small moleculeapprovedOrphan Drug FDA
Approved
May 26, 1995
Dexrazoxane is a cardioprotective drug used in patients with breast cancer to reduce cardiomyopathy associated with doxorubicin administration. Dexrazoxane is believed to act by two mechanisms: it inhibits DNA topoisomerase II and acts as a chelator for iron ions. — NCATS
Clinical trial activity
48 trials · 42 clinical orgs · 12 marketing orgs
Phase 1
12
Phase 2
33
Phase 3
16
Phase 4
1
Earliest trial started Apr 1, 1993 (NCT00001335)
Timeline
1990s
- Dec 17, 1991
Orphan Drug Designation
- Jan 1, 1993
Earliest Phase 2 Sponsor(trial)
- May 26, 1995
Earliest FDA Approval
- May 26, 1995
Pharmacia & Upjohn — NDA Secondary Org
- May 26, 1995
Pfizer — Marketing Organization
- May 26, 1995
Pfizer — NDA Secondary Org
- Jan 1, 1996
Earliest Phase 3 Sponsor(trial)
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
- Sep 28, 2004
West-Ward Pharmaceutical — Marketing Organization
- Sep 28, 2004
Hikma — Marketing Organization
- Sep 6, 2007
Clinigen — Marketing Organization
- Sep 6, 2007
Clinigene International Ltd — NDA Secondary Org
- Sep 6, 2007
Clinigen — NDA Secondary Org
2010s
- Oct 19, 2011
Mylan — Marketing Organization
- Oct 19, 2011
Auromedics Pharma — Marketing Organization
- Oct 19, 2011
Eugia Pharma — Marketing Organization
- Nov 28, 2016
Gland Pharma Ltd — Marketing Organization
2020s
- Mar 26, 2025
MSN Laboratories — Marketing Organization
Indications
Approved for
Studied for
- Anthracyclines · Phase 2/Phase 3
- Antineoplastic Combined Chemotherapy Protocols · Phase 2
- Bone Marrow Cells · Phase 2
- Breast Neoplasms · Phase 3
- Burkitt Lymphoma · Phase 1
- Cardiotoxicity · Phase 3
- Dexrazoxane · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Extravasation of Diagnostic and Therapeutic Materials · Phase 2/Phase 3
- Fibrosarcoma · Phase 2
- Ganglioneuroblastoma · Phase 3
- Healthy Volunteers · Phase 4
- Heart Defects, Congenital · Phase 1
- Hemangiosarcoma · Phase 2
- Hodgkin Disease · Phase 1
- Inflammatory Breast Neoplasms · Phase 3
- Intraocular Lymphoma · Phase 1
- Leiomyosarcoma · Phase 2
- Leukemia · Phase 3
- Leukemia, Hairy Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Liposarcoma · Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Lymphomatoid Granulomatosis · Phase 1
- Multiple Sclerosis · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 3
- Neuroblastoma · Phase 3
- Neurofibrosarcoma · Phase 2
- Osteosarcoma · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 3
- Sarcoma, Ewing · Phase 2
- Sarcoma, Myeloid · Phase 2
- Sarcoma, Synovial · Phase 2
- Sezary Syndrome · Phase 1
Mechanism of action
- IronCHELATING AGENT
Iron chelating agent
Not fully elucidated
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
Not fully elucidated
- IronSEQUESTERING AGENT
Iron sequestering agent
Approval history
- approvedPriority reviewAcceleratedMay 26, 1995
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1- Mol. weight
- 268.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1738 ↗
- WikipediaDexrazoxane ↗
- NCATS048L81261F ↗
- ChEMBLCHEMBL1200778 ↗
Also known as
- (+)-1,2-bis(3,5-dioxo-1-piperazinyl)propane
- (+)-1,2-bis(3,5-dioxo-1-piperazinyl)propane
- 4-[(2s)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
- 4-[(2s)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
- adr-529
- adr-529
- adr-529
- cardioxane
- cardioxane
- dexrazoxan
- dexrazoxan
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane
- dexrazoxane hcl
- dexrazoxane hcl
- dexrazoxane hcl
- dexrazoxane hydrochloride
- dexrazoxane hydrochloride
- dexrazoxane hydrochloride
- dexrazoxane hydrochloride
- dexrazoxane hydrochloride
- dexrazoxane hydrochloride
- dexrazoxano
- dexrazoxano
- dexrazoxanum
- dexrazoxanum
- dextrorazoxane
- dextrorazoxane
- icrf-187
- icrf-187
- (+)-(s)-4,4'-propylenedi-2,6-piperazinedione
- (+)-(s)-4,4'-propylenedi-2,6-piperazinedione
- savene
- totect
- totect
- totect
- zinecard
- zinecard
- zinecard
- zinecard
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06647953 | Phase 3 | Dec 17, 2024 | National Cancer Institute (NCI) |
| NCT06220032 | Phase 3 | Aug 15, 2024 | Free University of Amsterdam, HOVON - Dutch Haemato-Oncology Association, University of Amsterdam, Utrecht University |
| NCT06172296 | Phase 3 | Feb 14, 2024 | National Cancer Institute (NCI) |
| NCT06262438 | Phase 2 | Feb 6, 2024 | Daiichi Sankyo, Princess Maxima Center for Pediatric Oncology |
| NCT05292664 | Phase 1 | Dec 31, 2022 | AbbVie, Children's Cancer Research Fund United States, Gateway for Cancer Research, Harvard University, Servier, University of Colorado, Denver |
| NCT04997291 | Phase 1 | Apr 9, 2021 | Dell Children's Medical Center, University of Texas, Austin |
| NCT04293562 | Phase 3 | Apr 4, 2020 | National Cancer Institute (NCI) |
| NCT03930680 | Phase 4 | Jul 31, 2019 | University of Missouri |
| NCT03786783 | Phase 2 | Jan 14, 2019 | National Cancer Institute (NCI) |
| NCT03698227 | Phase 2 | Nov 12, 2018 | J. W. Goethe University |
| NCT03589729 | Phase 2 | Sep 19, 2018 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03007147 | Phase 3 | Jul 1, 2017 | National Cancer Institute (NCI) |
| NCT03164057 | Phase 2 | Jun 15, 2017 | St. Jude Children's Hospital |
| NCT03020030 | Phase 3 | Jan 1, 2017 | Baxalta, Harvard University |
| NCT02953184 | Phase 2 | Nov 1, 2016 | Jilin University |
| NCT02584309 | Phase 2 | Feb 22, 2016 | Washington University in St. Louis |
| NCT02519335 | Phase 1 | Sep 1, 2014 | Medical City Children's Hospital, Dallas, Mylan |
| NCT01871766 | Phase 2 | Dec 4, 2013 | St. Jude Children's Hospital |
| NCT01606878 | Phase 1 | Mar 1, 2013 | National Cancer Institute (NCI) |
| NCT01596088 | Phase 1/Phase 2 (Phase 2) | May 8, 2012 | Kissei Pharmaceuticals |
Showing 20 of 48 trials
Page 1 / 3
Organizations
Research & Development (42)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 25 | 18 | 3 | 1993 |
| Harvard University | Academic/Hospital | 6 | 6 | 3 | 1996 |
| University of Texas at Houston | Academic/Hospital | 4 | 4 | 2 | 1997 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 2 | 2001 |
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 1998 |
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 1 | 1997 |
| St. Jude Children's Hospital | Academic/Hospital | 2 | 2 | 1 | 2013 |
| University of Copenhagen | Academic/Hospital | 2 | 0 | 1 | 2001 |
| Valerio | For profit | 2 | 2 | 1 | 2001 |
| AbbVie | For profit | 1 | 0 | 1 | 2022 |
| Baxalta | For profit | 1 | 0 | 1 | 2017 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Children's Cancer Research Fund United States | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Daiichi Sankyo | For profit | 1 | 0 | 1 | 2024 |
| Dell Children's Medical Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Eisai | For profit | 1 | 0 | 1 | 2006 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Gateway for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Herbert Irving Comprehensive Cancer Center | Academic/Hospital | 1 | 0 | 1 | 1996 |
42 organizations
Page 1 / 3
Marketing (16)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Auromedics Pharma | For profit | MKTG | Oct 19, 2011 |
| Clinigen | For profit | MKTG | Sep 6, 2007 |
| Clinigen | For profit | NDA2 | Sep 6, 2007 |
| Clinigene International Ltd | For profit | NDA2 | Sep 6, 2007 |
| Eugia Pharma | For profit | MKTG | Oct 19, 2011 |
| Gland Pharma Ltd | For profit | MKTG | Nov 28, 2016 |
| Gland Pharma Ltd | For profit | MKTG | Nov 28, 2016 |
| Hikma | For profit | SYN | Sep 28, 2004 |
| Hikma | For profit | MKTG | Sep 28, 2004 |
| MSN Laboratories | For profit | MKTG | Mar 26, 2025 |
| Mylan | For profit | MKTG | Oct 19, 2011 |
| Pfizer | For profit | MKTG | May 26, 1995 |
| Pfizer | For profit | NDA2 | May 26, 1995 |
| Pharmacia | For profit | NDA | — |
| Pharmacia & Upjohn | For profit | NDA2 | May 26, 1995 |
| West-Ward Pharmaceutical | For profit | MKTG | Sep 28, 2004 |